A new study has found a new miraculous drug that could help trim down approximately 60% of cholesterol in the body thus lowering the risk of a heart attack by 25%.
A rapidly growing classification of cholesterol drugs that target a PCSK9 protein is being studied to become a very useful treatment. Clinical studies continue to find ways in helping lower the risks and causes of heart ailments.
Results that have been published by the New England Journal of Medicine were presented at a conference at the American College of Cardiology in Washington DC just yesterday, March 17.
Evolocumab (with the trade name Repatha) was found to lower the possible cause and risk of death by 20% due to cardiovascular diseases like stroke and heart attack. This is based on patients who are already under medication and taking drugs that are called statins. These drugs help control cholesterol count on the patients. On the other hand, Evolocumab was able to help reduce this risk by approximately 15%.
In 2015, the FDA or the U.S. Food and Drug Administration approved the use of the drug Evolocumab to be prescribed to patients who have high amounts of cholesterol. This drug actually showed signs of lowering the levels of “bad” LDL (Low-Density Lipoprotein) cholesterol that circulates the bloodstream by around 60%. Researchers have not yet found an actual evidence that Evolocumab could also protect patients against stroke or other cardiovascular diseases.
A clinical test has been done with the help of 27,000 patients internationally. There was an average fall of at least 60% on the cholesterol level of the tested patients.
According to this study, around 74 patients who have taken Evolocumab for 2 years, there is a single stroke or heart attack that is believed to be prevented.
Despite the success found in the cutting down of the cholesterol level in the patients, the published journal reported that there is quite no relative impact on the cardiovascular diseases’ mortality rate.
The first trial on statin was also published in a journal twenty years ago. With this, an Imperial College Professor from London, Peter Sever, thinks that this clinical discovery could be a huge help to many people who could be having different kinds of diseases and even stroke.
In the United Kingdom, there are around 2.3 million people who have coronary heart disease, as reported by the National Health Service. This disease has killed 73,000 people, too. Fatty substances are built up in the heart’s arteries making it difficult for a needed amount of blood to reach the heart itself.
Although statins have made an important impact on the reduction of cardiovascular diseases, not everybody supports this kind of medication since it can only lessen the cholesterol level only by a certain measure.
Researchers are very hopeful about the discovery. Such new approach helped to lessen the harming effects of PCSK9, which is a kind of molecule responsible for the reduction of the breaking of LDL cholesterol inside the liver. Being open to research and the making of new treatments that use this kind of approach could save many patients who have high levels of cholesterol in their bodies and the others who cannot tolerate the use of statins.